GlaxoSmithKline (GSK) continues to be the subject of takeover speculation, with Roche and Johnson & Johnson (J&J) now rumoured to be interested in bidding for the UK firm. There does not seem to ...
Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year. Sage Therapeutics has unanimously rejected Biogen's acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback